2025 6/15 Bio Convention 会前会
Morning Convention – Global Biomedical Pitch Competition Reception Part
Date: 6/15 9- 12 pm
Venue: Cambria Hotel Boston Downtown – Seaport Kennedy Room (6 W Broadway, Boston, MA 02127)
Organizers:
●Hong Kong Science and Technology Parks Corporation (HKSTP)
●Roche Accelerator
●Greenberg Traurig, LLP
●Boston Capital Investment Club
Value
●Unwind at an exclusive reception following the 2025 Biomedical Pitch Competition
●Connect ahead of the 2025 BIO International Convention in a relaxed, high-value setting
●Discover golden opportunities through insights from Asian biotech hub HKSTP and a renowned multinational Roche accelerator
Who should attend
●Global Entrepreneurs interested in fundraising
●Global MNCS interested in Asia Healthcare Innovation Hub
●Discover golden opportunities through insights from Asian biotech hub HKSTP and a renowned multinational accelerator
Topics
●Trend in cross board Biotech technology, Investment and M&A Deals
●Asia Healthcare Innovation Hub and Accelerator advantages
●Challenges in cross board Biotech deals
Agenda:
9:00 – 9:30am Check in and networking
9:30 – 10:30am Keynote Speakers
- CEO Albert Wong Hak-keung and delegate VIPs of HKSTP
- Dr. Qiusong Tang of Roche
- Dr. Can Cui , Shareholder of Greenberg Traurig, LLP
- VC representatives (including SOSV, Pagodatree Partners, etc)
10:30-11:30am Fireside Chat (topics: Biotech & Investment trend, Cross Border Incubation and Deals)
-Roche，HKSTP，GT，Pagodatree，GV20, etc
11:30-12:00pm Networking
Registration
https://bcic.ticketspice.com/2025-bpc-fireside-chat
– Albert Wong Hak-keung –
Albert Wong Hak-keung
CEO of Hong Kong Science and Technology Parks Corporation (HKSTP)
Mr Albert Wong commits in supporting Hong Kong’s tech startups and enterprises on their quest for innovation and growth. Since 2016, he has been working with a team that believes in entrepreneurial spirit, talent and networks cultivation, and transforming R&D endeavours into tangible innovations with commercial impact, being the keys in bringing HKSTP to be the preeminent foremost research and development hub in Hong Kong with a community of over 15,000 research professionals and 2,200 pioneering tech firms.
Prior to HKSTP, Albert spent over four decades at global conglomerates including PerkinElmer, Emerson, Caterpillar, Schlumberger and GE across US headquarters, Asia-Pacific and China CEO roles, understanding company growth, investment networks and market solutions brought his insights in contributing as a Member of the Green Technology and Finance Development Committee under the Financial Services and the Treasury Bureau, as well as the Advisory Committee for the Northern Metropolis under the Development Bureau, and to be an advocate for both the government and the I&T scenery.
– Qiusong Tang, Ph.D –
Qiusong Tang, Ph.D
Head of Roche Accelerator
Dr. Qiusong Tang leads Roche Accelerator, Roche’s first in-house accelerator globally, to expand Roche‘s external innovation capability in early stage research and development by partnering with scientists, entrepreneurs and venture capitalists to scout and incubate disruptive innovations.
Prior to joining Roche, Dr. Tang has more than 15 years of professional experience across research, strategy consulting and investment banking in Germany and Singapore, with IQVIA, Roland Berger and Bank of America Merrill Lynch. Dr. Tang studied neuroscience in University College London and obtained his PhD in computational neuroscience from Humboldt University of Berlin with 9 peer-reviewed publications in Science, Neuron, Nature Protocols, Cell Reports, The Journal of Neuroscience, etc., with more than 600 citations.
Dr. Tang is a member of Drug Information Association (DIA) Drug Discovery and Translational Medicine Professional Committee, Hong Kong Science and Technology Parks (HKSTP) Incu-Bio Programme Assessment Panel, and Shanghai Society for Aging and Neurodegenerative Diseases; and is reviewer of The Journal of Neuroscience, The Journal of Neurophysiology, and PLoS ONE.
– Dr. Can Cui –
Dr. Can Cui
Shareholder, Greenberg Traurig, LLP
Dr. Can Cui focuses his practice on technology transactions, investments and intellectual property (IP) protection in the life sciences and med-tech industries, with a particular emphasis on cross-border deals involving Asia. His work encompasses technology licensing and acquisition, collaboration and strategic partnerships, joint ventures, and various forms of investment.
Can frequently represents life sciences and med-tech companies, from startups to multinational corporations, in worldwide and U.S.-China life sciences licensing and collaboration transactions, from target or drug discovery phase to clinical stage and beyond. His representation covers the entire value chain, and includes contract research, manufacture and supply, clinical trials, commercialization and distribution arrangements.
In the realm of private equity and venture capital, he regularly conducts IP due diligence and negotiates investment documentation for institutional and individual investors, and emerging and established life sciences and med-tech companies. Additionally, Can advises clients on IP aspects of mergers and acquisitions.
– Shirley Liu, PhD –
Shirley Liu, PhD, Chief Executive Officer, Co-Founder of GV20
Dr. X. Shirley Liu is the co-founder and CEO of GV20 Therapeutics, a clinical-stage AI-based next generation biotherapeutics company. GV20’s lead program GV20-0251, a monoclonal antibody against a novel immune checkpoint IGSF8, is the world’s first AI-designed antibody against an AI-predicted target in the clinic. The power of GV20’s AI platform is demonstrated by GV20-0251’s unprecedented 3-year timeline from target research to IND, and validated by GV20-0251’s favorable safety and promising monotherapy efficacy in advanced metastatic cancer patients. Dr. Liu received her PhD in Biomedical Informatics and PhD minor in Computer Science from Stanford University in 2002. Before joining GV20, she was a Professor of Biostatistics and Computational Biology at the Department of Data Science at Dana-Farber Cancer Institute (DFCI) and Harvard University. She has published over 270 papers and has an H-index of 124. She is a fellow of the International Society of Computational Biology (ISCB), American Institute for Medical and Biological Engineering (AIMBE) and was a Breast Cancer Research Foundation Investigator (2017-2021). She is a recipient of the Sloan Research Fellowship (2008), Weitzman Outstanding Early Career Investigator Award from the Endocrine Society (2016), ISCB Innovator Award (2020), and the Benjamin Franklin Award for Open Access in the Life Sciences (2020). Her lab has mentored 28 PhD and postdoctoral trainees to independent academic careers.
– Charles Li –
Charles Li, CFA, Managing Director of PagodaTree Partners.
Charles has over 20 years of investment experience. An expert in biotech and healthcare investment, and cross border transactions, he has extensive resources in global capital markets.
Previously, Charles was a director of Deloitte. He also worked at Credit Suisse and Fannie Mae. He received Masters’ degree from Olin Business Washington University and B.E. from Tianjin University.